WO2005076999A3 - Methods and compositions for combination rnai therapeutics - Google Patents

Methods and compositions for combination rnai therapeutics Download PDF

Info

Publication number
WO2005076999A3
WO2005076999A3 PCT/US2005/003858 US2005003858W WO2005076999A3 WO 2005076999 A3 WO2005076999 A3 WO 2005076999A3 US 2005003858 W US2005003858 W US 2005003858W WO 2005076999 A3 WO2005076999 A3 WO 2005076999A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
rnai therapeutics
sirna molecules
combination rnai
Prior art date
Application number
PCT/US2005/003858
Other languages
French (fr)
Other versions
WO2005076999A2 (en
Inventor
Bao-Jian Li
Patrick Y Lu
Martin C Woodle
Frank Y Xie
Original Assignee
Intradigm Corp
Bao-Jian Li
Patrick Y Lu
Martin C Woodle
Frank Y Xie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corp, Bao-Jian Li, Patrick Y Lu, Martin C Woodle, Frank Y Xie filed Critical Intradigm Corp
Priority to AU2005213485A priority Critical patent/AU2005213485A1/en
Priority to EP05713043A priority patent/EP1713819A4/en
Priority to CA002555531A priority patent/CA2555531A1/en
Publication of WO2005076999A2 publication Critical patent/WO2005076999A2/en
Priority to US11/792,179 priority patent/US8691781B2/en
Priority to CA002586250A priority patent/CA2586250A1/en
Priority to JP2007539358A priority patent/JP2009526516A/en
Priority to CNA2005800450233A priority patent/CN101103111A/en
Priority to PCT/US2005/040048 priority patent/WO2006121464A2/en
Priority to CN2011104403455A priority patent/CN102618541A/en
Priority to EP05857827A priority patent/EP1817416A2/en
Publication of WO2005076999A3 publication Critical patent/WO2005076999A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods containing mixtures of siRNA molecules that target genes associated with disease are provided. The mixtures of siRNA molecules provide greater efficacy in reducing expression of disease-associated genes than individual siRNA molecules.
PCT/US2005/003858 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics WO2005076999A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2005213485A AU2005213485A1 (en) 2004-02-05 2005-02-07 Methods and compositions for combination RNAi therapeutics
EP05713043A EP1713819A4 (en) 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics
CA002555531A CA2555531A1 (en) 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics
EP05857827A EP1817416A2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
CA002586250A CA2586250A1 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
US11/792,179 US8691781B2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
JP2007539358A JP2009526516A (en) 2004-11-05 2005-11-04 Composition for treating respiratory viral infection and use thereof
CNA2005800450233A CN101103111A (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
PCT/US2005/040048 WO2006121464A2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
CN2011104403455A CN102618541A (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54177604P 2004-02-05 2004-02-05
US60/541,776 2004-02-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/792,179 Continuation-In-Part US8691781B2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use

Publications (2)

Publication Number Publication Date
WO2005076999A2 WO2005076999A2 (en) 2005-08-25
WO2005076999A3 true WO2005076999A3 (en) 2006-07-06

Family

ID=34860217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/003858 WO2005076999A2 (en) 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics

Country Status (5)

Country Link
EP (1) EP1713819A4 (en)
CN (1) CN101044152A (en)
AU (1) AU2005213485A1 (en)
CA (1) CA2555531A1 (en)
WO (1) WO2005076999A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
CA2586250A1 (en) * 2004-11-05 2006-11-16 Intradigm Corporation Compositions for treating respiratory viral infections and their use
CN102600480B (en) 2005-01-07 2015-07-22 阿尔尼拉姆医药品有限公司 RNAI modulation of RSV and therapeutic uses thereof
CA2604441A1 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
CA2619950A1 (en) * 2005-08-26 2007-03-01 Henry Ford Health System Methods and compositions for investigation and treatment of cancer using a g-protein coupled eicosanoid receptor
JPWO2007080902A1 (en) * 2006-01-11 2009-06-11 協和発酵キリン株式会社 Composition for suppressing target gene expression in eyeball and therapeutic agent for disease in eyeball
US20100279408A1 (en) * 2006-11-27 2010-11-04 Enzon Pharmaceuticals, Inc. Polymeric short interfering rna conjugates
AU2006351974A1 (en) * 2006-12-21 2008-06-26 Intradigm Corporation Inhibitory polynucleotide compositions and methods for treating cancer
PL2308514T3 (en) 2007-03-23 2013-11-29 To Bbb Holding B V Conjugates for targeted drug delivery across the blood-brain barrier
EP2215102B1 (en) * 2007-10-01 2016-02-17 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
JP2011504170A (en) 2007-11-06 2011-02-03 サーナオミクス、インク． Multi-targeted RNAi therapeutics for scarless injury healing in the skin
US8541568B2 (en) 2008-05-24 2013-09-24 Hai Yan Compositions and methods using siRNA molecules for treatment of gliomas
US9012622B2 (en) 2008-12-31 2015-04-21 Patrick Y. Lu Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
CN102985546A (en) 2010-05-04 2013-03-20 圣诺制药公司 Combinations of TGF-beta and Cox-2 inhibitors and methods for their therapeutic application
WO2012016139A2 (en) 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
CN103597074A (en) 2011-06-16 2014-02-19 Isis制药公司 Antisense modulation of fibroblast growth factor receptor 4 expression
CN103007291B (en) * 2011-09-26 2015-04-29 苏州圣诺生物医药技术有限公司 Composition for treating eye diseases by double-target/multi-target small nucleic acid and applications of composition
CN102399820B (en) * 2011-09-27 2013-06-12 天津佰思普生物科技有限公司 Small interfering RNA directed at HPV16 E7 gene and its application
WO2014011512A1 (en) 2012-07-08 2014-01-16 Sirnaomics, Inc. Compositions and methods for "resistance-proof" sirna therapeutics for influenza
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN106771252A (en) * 2017-01-13 2017-05-31 福建医科大学 Application and kit of the AMACR albumen in prognosis evaluation reagent kit after preparing Liver Cancer Operation
CN111620939B (en) * 2019-10-25 2021-01-01 南京市妇幼保健院 Polypeptide ZYX for treating or assisting in treating ovarian cancer36-58
CA3165825A1 (en) * 2020-01-23 2021-07-29 Danny Tang Composition and methods of rnai prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-ncov)
CN114196785A (en) * 2020-09-18 2022-03-18 北京大学人民医院 Biomarker for susceptibility of cytomegalovirus to megakaryocytes after allogeneic hematopoietic stem cell transplantation and application thereof
CN114452393A (en) * 2022-02-22 2022-05-10 南方科技大学 Application of PINCH-1 protein as target in preparation of medicine for treating pulmonary fibrosis
CN116421616A (en) * 2022-03-17 2023-07-14 圣诺生物医药技术(苏州)有限公司 Nucleic acid interference pharmaceutical composition and medicine for treating colorectal cancer, gastric cancer and prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243541A1 (en) * 2002-06-12 2003-12-31 Ambion, Inc. Methods and compositions relating to labeled rna molecules that reduce gene expression
CN1922330A (en) * 2003-04-25 2007-02-28 因特拉迪格姆公司 Rnai agents for anti-sars coronavirus therapy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] "Homo sapiens epidermal growth factor (EGF) mRNA sequence", XP003019070, Database accession no. (NM_001963) *
DATABASE GENBANK [online] "Homo sapiens vascular endothelial growth factor receptor 2 (KDR) mRNA sequence", XP003019069, Database accession no. (AF063658) *
DOWNWARD J.: "Science, medicine, and the future: RNA interference", BMJ, vol. 328, 2004, pages 1245 - 1248, XP003002362 *
ELBASHIR ET AL.: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, 24 May 2001 (2001-05-24), pages 494 - 498, XP001167187 *
HAMMOND ET AL.: "Post-Transcriptional gene silencing by double-stranded RNA", NATURE REVIEWS, vol. 2, February 2001 (2001-02-01), pages 110 - 119, XP001146153 *
HANNON ET AL.: "Unlocking the potential of the human genome with RNA interference", NATURE, vol. 431, 2004, pages 371 - 378, XP003002623 *
ISHIBASHI ET AL.: "Expression cloning of a human dual-specificity phosphatase", PROC. NATL. ACAD. SCI., vol. 89, 1992, pages 12170 - 12174, XP008072750 *
PAROO ET AL.: "Challenges for RNAi in vivo", TRENDS IN BIOTECHNOLOGY, vol. 22, August 2004 (2004-08-01), pages 390 - 394, XP002299924 *
See also references of EP1713819A4 *
SHIRAI ET AL.: "Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor", NATURE, vol. 313, no. 6005, 28 February 1985 (1985-02-28), pages 803 - 806, XP002140139 *

Also Published As

Publication number Publication date
WO2005076999A2 (en) 2005-08-25
CN101044152A (en) 2007-09-26
EP1713819A4 (en) 2007-11-14
CA2555531A1 (en) 2005-08-25
EP1713819A2 (en) 2006-10-25
AU2005213485A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
WO2005076999A3 (en) Methods and compositions for combination rnai therapeutics
IL181238A (en) Sirna molecules that inhibit rtp801 gene expression and therapeutic uses thereof
WO2006015258A3 (en) Methods and compositions related to argonaute proteins
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
EP2395012B8 (en) Modified siRNA molecules and uses thereof
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2010033225A3 (en) Compositions and methods for the specific inhibition of gene expression by dsrna
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
WO2009151546A3 (en) Methods for treating spinal muscular atrophy
IL231688A0 (en) Dsrna for inhibiting the expression of human eg5 gene in a cell, a pharmaceutical composition comprising same, a method and vector
MX348735B (en) MESENCHYMAL STEM CELLS EXPRESSING TNF-a RECEPTOR.
EP1976567A4 (en) Natural antisense and non-coding rna transcripts as drug targets
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2005117557A3 (en) Expression system
WO2007120842A3 (en) Methods and compositions for targeting c-rel
WO2008131419A3 (en) Glycoconjugates of rna interference agents
WO2006029258A3 (en) Aptamer medicinal chemistry
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
EP1951263A4 (en) Multitargeting interfering rnas having two active strands and methods for their design and use
WO2007092182A3 (en) Rna interference agents for therapeutic use
WO2005118824A8 (en) Methods and compositions for the inhibition of gene expression
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2555531

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005713043

Country of ref document: EP

Ref document number: 2005213485

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005213485

Country of ref document: AU

Date of ref document: 20050207

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005213485

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580011956.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005713043

Country of ref document: EP